A Hypoxia-Inducible CAR-T Cell Targeting AXL and CD73 for Advanced Gastric Cancer

NCT07333573 | Not Yet Recruiting Phase 1

• 1 other identifier: ZSGC-CD73AXL-CART
• Study Type: interventional
• Target: 42
• Locations: 1 country
• Sites: 1

Brief Summary

This is a single-arm, open-label clinical study evaluating the safety and preliminary efficacy of a novel hypoxia-inducible, bispecific CD73/AXL-targeting CAR-T cell product, XW-LTH-03, in patients with stage IV gastric cancer (GC). The primary objective is to assess the safety and tolerability of XW-LTH-03 infusions. Secondary objectives include the evaluation of its antitumor efficacy and the characterization of its pharmacokinetic profile by measuring the in vivo expansion and persistence of the CAR-T cells. Exploratory analyses aim to identify potential biomarkers associated with clinical response and toxicity, as well as to investigate the cellular and molecular mechanisms underlying potential treatment resistance.

Conditions

Stage IV Gastric Cancer

Outcome Measures

Primary Outcomes (3)

• Incidence of Adverse Events (AEs) and Serious Adverse Events (SAEs)

  3 months

• Incidence of Dose-Limiting Toxicities (DLTs)

  3 months

• Maximum Tolerated Dose (MTD) or Recommended Phase II Dose (RP2D)

  3 months

Study Arms (1)

XW-LTH-03 Infusion

EXPERIMENTAL

Biological: XW-LTH-03 Infusion

Interventions

XW-LTH-03 Infusion BIOLOGICAL

CD73/AXL-Targeting Hypoxia-Inducible CAR-T

XW-LTH-03 Infusion

Eligibility Criteria

• Age: 18 Years - 75 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Aged 18 to 75 years, male or female.
• Clinically judged as unresectable Stage IV gastric cancer that has progressed on or is intolerant to standard therapy, or patients who voluntarily forego standard therapy.
• Patients must provide tumor tissue samples, with positive AXL and CD73 confirmed by immunohistochemical (IHC) staining at a central laboratory: AXL positivity rate ≥50% with staining intensity ≥++, and CD73 positivity rate ≥30% with staining intensity ≥+.
• ECOG Performance Status score of ≤ 1.
• Life expectancy of ≥ 3 months.
• At least one measurable lesion (≥ 1 cm).
• More than 4 weeks since the last failed treatment, and any toxicities from previous treatments must have recovered to Grade ≤ 1.
• Adequate organ function and bone marrow reserve, as defined by the following laboratory values within a specified period before enrollment:
• \. Hemoglobin (Hb) ≥ 90 g/L. 2. Absolute Neutrophil Count (ANC) ≥ 1.0 × 10\^9/L. 3. Absolute Lymphocyte Count ≥ 0.5 × 10\^9/L. 4. Platelet count ≥ 100 × 10\^9/L. 5. Serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 3 × upper limit of normal (ULN).
• \. Serum amylase and lipase ≤ 1.0 × ULN. 7. Total bilirubin ≤ 1.5 × ULN. 8. Serum creatinine ≤ 1.5 × ULN or creatinine clearance ≥ 50 mL/min (calculated by the Cockcroft-Gault formula).
• \. Prothrombin Time (PT) or International Normalized Ratio (INR), and Partial Thromboplastin Time (PTT) \< 1.5 × ULN. (Patients receiving warfarin or heparin anticoagulation therapy may be enrolled if no underlying abnormality in these parameters is suspected, but require close monitoring with at least weekly testing until INR is stable).
• \. Adequate cardiac and pulmonary function. 10. Women of childbearing potential must have a negative pregnancy test within 7 days before treatment initiation. All subjects must agree to use effective contraception during the treatment period and for 1 year thereafter.
• \. Voluntary signing of a written informed consent form, good compliance, and willingness to cooperate with follow-up.

You may not qualify if:

• Active, known, or highly suspected autoimmune disease.
• Patients with brain metastases who have active central nervous system symptoms. (Note: Patients with brain metastases who completed radiotherapy at least 3 months prior to enrollment and remain asymptomatic from CNS disease may be eligible).
• Active, uncontrolled systemic infection.
• Receiving high-dose corticosteroids (\>10 mg/day of methylprednisolone or equivalent doses of other corticosteroids) or other immunosuppressive therapy within 14 days prior to enrollment.
• History of severe allergy to other monoclonal antibodies.
• Intolerance or allergy to the investigational drug.
• History of interstitial lung disease.
• Evidence of organ failure:
• Cardiac: Class III or IV heart failure (per NYHA or other applicable criteria).
• Hepatic: Class C liver function as per Child-Pugh score.
• Renal: Renal failure or uremia stage.
• Pulmonary: Symptoms of severe respiratory failure.
• Neurological: Impaired consciousness.
• Active Hepatitis B (HBsAg positive with detectable HBV DNA), active Hepatitis C (HCV RNA positive), or HIV antibody positive.
• History of organ transplantation.

Sponsors & Collaborators

• Shanghai Zhongshan Hospital: lead
• SHANGHAI SINOBAY BIOTECHNOLOGY CO., LTD: collaborator

Study Sites (1)

Fudan University Zhongshan Hospital

Shanghai, Shanghai Municipality, 200032, China

Location

MeSH Terms

Conditions

Stomach Neoplasms

Condition Hierarchy (Ancestors)

Gastrointestinal Neoplasms; Digestive System Neoplasms; Neoplasms by Site; Neoplasms; Digestive System Diseases; Gastrointestinal Diseases; Stomach Diseases

Central Study Contacts

Zhaoming Wang

CONTACT

021-64041990; wang.zhaoming@zs-hospital.sh.cn

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: September 23, 2025
• First Posted: January 12, 2026
• Study Start: January 1, 2026
• Primary Completion (Estimated): June 30, 2027
• Study Completion (Estimated): June 30, 2027
• Last Updated: January 12, 2026

Record last verified: 2025-12

Locations

CN (1)